Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Challenges to National Cancer Institute-Supported Cooperative Group Clinical Trial Participation: An ASCO Survey of Cooperative Group Sites.

Literature DB >> 20808551

Challenges to National Cancer Institute-Supported Cooperative Group Clinical Trial Participation: An ASCO Survey of Cooperative Group Sites.

Allison R Baer¹, Chelsey A Kelly, Suanna S Bruinooge, Carolyn D Runowicz, Douglas W Blayney.

Abstract

Anecdotal information regarding clinical research sites limiting participation in NCI-funded cooperative group studies prompted ASCO to collect data on and investigate the reasons behind this trend.

Entities: Disease

Year: 2010 PMID： 20808551 PMCID： PMC2868633 DOI： 10.1200/JOP.200028

Source DB: PubMed Journal: J Oncol Pract ISSN： 1554-7477 Impact factor: 3.840

8 in total

1. Oncologist's role critical to clinical trial enrollment.

Authors: R Finn
Journal: J Natl Cancer Inst Date: 2000-10-18 Impact factor: 13.506

2. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

Authors: P Bonomi; K Kim; D Fairclough; D Cella; J Kugler; E Rowinsky; M Jiroutek; D Johnson
Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544

3. The costs of conducting clinical research.

Authors: Ezekiel J Emanuel; Lowell E Schnipper; Deborah Y Kamin; Jenifer Levinson; Allen S Lichter
Journal: J Clin Oncol Date: 2003-10-14 Impact factor: 44.544

4. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Authors: Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal: JAMA Date: 2006-06-05 Impact factor: 56.272

5. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

Authors: Gregory Cairncross; Brian Berkey; Edward Shaw; Robert Jenkins; Bernd Scheithauer; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperierre; Minesh Mehta; Walter Curran
Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544

6. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245

7. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245

8. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

Authors: Ronald P Dematteo; Karla V Ballman; Cristina R Antonescu; Robert G Maki; Peter W T Pisters; George D Demetri; Martin E Blackstein; Charles D Blanke; Margaret von Mehren; Murray F Brennan; Shreyaskumar Patel; Martin D McCarter; Jonathan A Polikoff; Benjamin R Tan; Kouros Owzar
Journal: Lancet Date: 2009-03-18 Impact factor: 79.321

8 in total

5 in total

5. Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications.

Authors: Joseph M Unger; Van T Nghiem; Dawn L Hershman; Riha Vaidya; Michael LeBlanc; Charles D Blanke
Journal: JAMA Netw Open Date: 2019-09-04